The P-Ib (TROPION-Lung02) trial evaluating datopotamab deruxtecan (4 & 6mg/kg) + pembrolizumab (200mg) with/out Pt CT (carboplatin or cisplatin) in patients with advanced or metastatic NSCLC without actionable genomic alterations
The results showed a promising clinical activity along with a tolerable safety profile. In an interim analysis, ORR in the overall population of 37% with a median follow-up of 6.5mos. in patients with datopotamab deruxtecan & pembrolizumab; ORR (41%) with a median follow-up of 4.4 mos. in patients with datopotamab deruxtecan, pembrolizumab & platinum CT, DCR (84%) in both combination therapy
In prior untreated patients, ORRs (62% & 50%) in doublet & triplet therapy; PRs (8 & 10); DCR (100% & 90%); grade ≥3 TEAEs (40% & 60%)
Ref: AstraZeneca | Image: AstraZeneca
